Trial Profile
An Open-label, Randomized, Crossover Relative Bioavailability Study of a New Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Current Solution Formulation (Powder in Bottle (PIB), After Single Dose Oral Administration in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2014
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record